New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 1, 2013
09:17 EDTMRK, AIXG, LXRX, RH, WAG, EDG, MYGN, BTN, PSTIOn The Fly: Pre-market Movers
HIGHER: Merck (MRK), up 3% after announcing restructuring plans, including intent to cut about 20% of workforce by end 2015... Lexicon (LXRX), up 21% after achieving positive clinical trial results for potential diabetes drug... Edgen Group (EDG), up 57% after agreeing to be acquired by Sumitomo Corp. for $12.00 per share... Myriad Genetics (MYGN), up 11% after Piper Jaffray says should be bought on any weakness and stock upgraded at Ladenburg... Ballantyne Strong (BTN), up 6% after acquiring Convergent Media Systems... Pluristem (PSTI), up 5% after PLX cells demonstrate efficacy in preclinical study for GvHD. LOWER: Walgreens (WAG), down 0.5% after Q4 earnings report... Aixtron (AIXG), down 4% after downgrade at Canaccord... Restoration Hardware (RH), down 3% after holder CP Home files to sell about 4M shares.
News For MRK;AIXG;LXRX;RH;WAG;EDG;MYGN;BTN;PSTI From The Last 14 Days
Check below for free stories on MRK;AIXG;LXRX;RH;WAG;EDG;MYGN;BTN;PSTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2014
06:32 EDTMRKPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
18:00 EDTMRKU.S. FDA approves Merck's GRASTEK
Subscribe for More Information
08:59 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:25 EDTLXRXLexicon to host conference call
Subscribe for More Information
06:10 EDTLXRXLexicon achieves positive results in Type 1 diabetes clinical trial
Lexicon Pharmaceuticals announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. In the placebo-controlled, double-blind, 28-day study, LX4211 reduced the total daily mealtime bolus insulin dose by 32% compared to 6% for placebo, while significantly improving glycemic control with a mean HbA1c reduction of 0.55% in the LX4211-treated group compared to a reduction of only 0.06% with placebo. This improvement was accompanied by significant improvement in the time spent in a glucose range of 70-180 mg/dl, a significant reduction in time in hyperglycemic range, and no increase in hypoglycemia. Multiple measures indicated that LX4211 treatment resulted in reduced variability in blood glucose levels. Overall, LX4211 was well tolerated with no discontinuations of study medication due to adverse events.
06:08 EDTMRKMerck volatility elevated into Q1 and outlook
Subscribe for More Information
April 13, 2014
16:41 EDTWAGWalgreens investor group urges for re-domiciling tax base to Europe, FT says
Subscribe for More Information
April 11, 2014
09:39 EDTRHWilliams-Sonoma should buy Restoration Hardware. says BB&T
Subscribe for More Information
09:08 EDTWAGWalgreens has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO Greg Wasson on April 17 at 2 pm.
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
11:28 EDTWAGWalgreens management to meet with BB&T
Subscribe for More Information
11:23 EDTWAGRite Aid hits 52-week high after results, sales view top estimates
Shares of retail drugstore Rite Aid (RAD) are rallying after the company's fourth quarter results and fiscal 2015 revenue outlook topped analysts' consensus estimates. WHAT'S NEW: This morning, Rite Aid reported fourth quarter adjusted earnings per share of 10c and revenue of $6.6B, compared to expectations of 4c and $6.54B, respectively. Q4 same store sales increased 2.1%. Rite Aid forecast FY15 EPS of 31c-42c, compared to the consensus of 35c. FY15 revenue was seen at $26B-$26.5B, ahead of the consensus $25.75B. FY15 same-store sales are expected by the company to be up 2.5%-4.5%. WHAT'S NOTABLE: Rite Aid also announced it has acquired RediClinic, which currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Rite Aid CEO John Standley said, “Our recent acquisitions of Health Dialog and RediClinic, our expanded partnership with McKesson and our continued commitment to investing in our store base have positioned us to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail healthcare company.” PRICE ACTION: In late morning trading, Rite Aid rose 71c, or about 11%, to $7.11 on more than twice its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week high of $7.39. Including today's advance, the stock is up approximately 300% over the past twelve months. OTHERS TO WATCH: Other retail drugstore operators include Walgreen Company (WAG) and CVS Caremark (CVS).
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-naïve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
April 9, 2014
11:43 EDTMRKGilead defended by analysts after recent pullback
Subscribe for More Information
07:23 EDTMRKEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTMRKReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use